Skip to main content
. 2026 Oct 14;3(1):e20260040. doi: 10.70962/jhi.20260040

Figure 9.

Two line graphs depict changes in lymphoproliferation parameters over time. Panel A: A line graph shows the mean untransformed sum of product of diameters of index lymph nodes in square centimeters across DFT or RCT screening, end of DFT or RCT, and open-label extension, with the y-axis ranging from 0 to 45 square centimeters. Three lines represent the overall, previous leniolisib, and previous placebo groups, with error bars showing standard deviation. Panel B: A line graph shows the mean spleen 3D volume in cubic centimeters across DFT or RCT screening, end of DFT or RCT, and open-label extension, with the y-axis ranging from 0 to 1000 cubic centimeters. Three lines represent the overall, previous leniolisib, and previous placebo groups, with a gray box indicating the adult reference range and error bars showing standard deviation.

Changes in lymphoproliferation parameters. (A) Mean untransformed SPD of index lymph nodes. Reference range (≤1.5 × 1.5 cm) not shown, as up to six lymph nodes may be counted per patient. n values for total cohort (overall), prior leniolisib, and prior placebo are as follows: 30, 22, and 8. (B) Mean spleen 3D volume. Patients are grouped into the following categories: overall (total cohort), previous leniolisib (received leniolisib prior to OLE), and previous placebo (received placebo prior to OLE). The gray box in B indicates the reference range for adults. n values for total cohort (overall), prior leniolisib, and prior placebo are as follows: 31, 23, and 8. Error bars are SD. Imaging for the OLE study was optional and collected at either ED 168 or 252. Two patients who were not previously enrolled in the DFT or the RFT did not have available baseline images and were excluded from the analysis.